Home Cart 0 Sign in  
X

[ CAS No. 445-29-4 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 445-29-4
Chemical Structure| 445-29-4
Chemical Structure| 445-29-4
Structure of 445-29-4 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 445-29-4 ]

Related Doc. of [ 445-29-4 ]

Alternatived Products of [ 445-29-4 ]

Product Details of [ 445-29-4 ]

CAS No. :445-29-4 MDL No. :MFCD00002405
Formula : C7H5FO2 Boiling Point : -
Linear Structure Formula :- InChI Key :NSTREUWFTAOOKS-UHFFFAOYSA-N
M.W : 140.11 Pubchem ID :9935
Synonyms :

Calculated chemistry of [ 445-29-4 ]

Physicochemical Properties

Num. heavy atoms : 10
Num. arom. heavy atoms : 6
Fraction Csp3 : 0.0
Num. rotatable bonds : 1
Num. H-bond acceptors : 3.0
Num. H-bond donors : 1.0
Molar Refractivity : 33.36
TPSA : 37.3 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -5.9 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.13
Log Po/w (XLOGP3) : 1.77
Log Po/w (WLOGP) : 1.94
Log Po/w (MLOGP) : 2.04
Log Po/w (SILICOS-IT) : 1.64
Consensus Log Po/w : 1.7

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.56

Water Solubility

Log S (ESOL) : -2.2
Solubility : 0.88 mg/ml ; 0.00628 mol/l
Class : Soluble
Log S (Ali) : -2.17
Solubility : 0.945 mg/ml ; 0.00674 mol/l
Class : Soluble
Log S (SILICOS-IT) : -2.02
Solubility : 1.33 mg/ml ; 0.00948 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.0

Safety of [ 445-29-4 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 445-29-4 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 445-29-4 ]
  • Downstream synthetic route of [ 445-29-4 ]

[ 445-29-4 ] Synthesis Path-Upstream   1~40

  • 1
  • [ 445-29-4 ]
  • [ 1006-19-5 ]
Reference: [1] Journal of Heterocyclic Chemistry, 1989, vol. 26, p. 257 - 264
  • 2
  • [ 445-29-4 ]
  • [ 393-52-2 ]
YieldReaction ConditionsOperation in experiment
70% With thionyl chloride In toluene at 50℃; for 7 h; Reflux Step I
2-fluorobenzoyl chloride (Intermediate a)
To 100mL of toluene were added 0.714 mol of 2-fluorobenzoic acid (100 g) then the mixture was heated to 50°C and added 5.7 mol (414mL) sulfoxide chloride .The reaction mixture was refluxed for 7 h.
After completion of the reaction, sulfoxide chloride was evaporated to give 2-fluorobenzoyl chloride 79 g. Yield: 70percent.
70% With thionyl chloride In toluene at 50℃; for 7 h; To 100 mL of toluene were added 0.714 mol of 2-fluorobenzoic acid (100 g) then the mixture was heated to 50° C. and added 5.7 mol (414 mL) sulfoxide chloride.
The reaction mixture was refluxed for 7 h.
After completion of the reaction, sulfoxide chloride was evaporated to give 2-fluorobenzoyl chloride 79 g. Yield: 70percent.
Reference: [1] Phosphorus, Sulfur and Silicon and Related Elements, 1996, vol. 113, # 1-4, p. 179 - 207
[2] Journal of Organometallic Chemistry, 2005, vol. 690, # 17, p. 3918 - 3928
[3] Organic and Biomolecular Chemistry, 2009, vol. 7, # 23, p. 4886 - 4894
[4] Patent: EP2799437, 2014, A1, . Location in patent: Paragraph 0055
[5] Patent: US2014/364431, 2014, A1, . Location in patent: Paragraph 0186
[6] Russian Journal of Organic Chemistry, 2010, vol. 46, # 3, p. 318 - 321
[7] Zeitschrift fuer Physikalische Chemie (Leipzig), 1930, vol. <B> 10, p. 106,119
[8] Chemische Berichte, 1931, vol. 64, p. 1455,1480[9] Chemische Berichte, 1933, vol. 66, p. 286,291
[10] Nippon Kagaku Zasshi, 1958, vol. 79, p. 1428,1430[11] Chem.Abstr., 1960, p. 5518
[12] Journal of Heterocyclic Chemistry, 1989, vol. 26, p. 257 - 264
[13] Journal of Medicinal Chemistry, 1983, vol. 26, # 5, p. 765 - 768
[14] Magnetic Resonance in Chemistry, 1993, vol. 31, # 9, p. 836 - 840
[15] Journal of Medicinal Chemistry, 2006, vol. 49, # 15, p. 4512 - 4516
[16] Chemical and Pharmaceutical Bulletin, 1992, vol. 40, # 1, p. 202 - 211
[17] Synthesis, 1996, # 4, p. 514 - 518
[18] Journal of Heterocyclic Chemistry, 1998, vol. 35, # 1, p. 225 - 229
[19] Journal of Medicinal Chemistry, 1999, vol. 42, # 6, p. 981 - 991
[20] Pesticide Science, 1994, vol. 41, # 2, p. 139 - 148
[21] Chemical and Pharmaceutical Bulletin, 2000, vol. 48, # 1, p. 21 - 31
[22] Bioorganic and Medicinal Chemistry Letters, 2002, vol. 12, # 2, p. 171 - 175
[23] Bioorganic and Medicinal Chemistry, 2002, vol. 10, # 12, p. 3933 - 3939
[24] Organic Letters, 2003, vol. 5, # 25, p. 4795 - 4798
[25] Journal of Organic Chemistry, 2003, vol. 68, # 26, p. 10195 - 10198
[26] Journal of Medicinal Chemistry, 2005, vol. 48, # 3, p. 839 - 848
[27] European Journal of Medicinal Chemistry, 2006, vol. 41, # 12, p. 1421 - 1429
[28] Journal of Medicinal Chemistry, 2007, vol. 50, # 6, p. 1365 - 1379
[29] Bioorganic and Medicinal Chemistry, 2008, vol. 16, # 8, p. 4233 - 4241
[30] Journal of Organometallic Chemistry, 2008, vol. 693, # 18, p. 3081 - 3091
[31] Journal of Medicinal Chemistry, 2009, vol. 52, # 4, p. 1115 - 1125
[32] Patent: US2005/239767, 2005, A1, . Location in patent: Page/Page column 10
[33] Bioorganic and Medicinal Chemistry Letters, 2009, vol. 19, # 19, p. 5716 - 5721
[34] Bioorganic and Medicinal Chemistry Letters, 2010, vol. 20, # 13, p. 3936 - 3940
[35] Letters in Drug Design and Discovery, 2010, vol. 7, # 3, p. 188 - 193
[36] Journal of Fluorine Chemistry, 2009, vol. 130, # 11, p. 1028 - 1034
[37] Journal of Medicinal Chemistry, 2010, vol. 53, # 19, p. 7011 - 7020
[38] Chemical Biology and Drug Design, 2010, vol. 75, # 5, p. 489 - 493
[39] Synthesis, 2010, # 24, p. 4273 - 4281
[40] ACS Medicinal Chemistry Letters, 2011, vol. 2, # 6, p. 481 - 484
[41] Medicinal Chemistry, 2010, vol. 6, # 4, p. 211 - 218
[42] Angewandte Chemie - International Edition, 2011, vol. 50, # 39, p. 9081 - 9084
[43] European Journal of Medicinal Chemistry, 2011, vol. 46, # 9, p. 3551 - 3563
[44] Journal of Medicinal Chemistry, 2012, vol. 55, # 7, p. 3170 - 3181
[45] Journal of Medicinal Chemistry, 2012, vol. 55, # 9, p. 4189 - 4204
[46] Bioorganic and Medicinal Chemistry, 2012, vol. 20, # 12, p. 3915 - 3924
[47] Synthetic Communications, 2012, vol. 42, # 23, p. 3524 - 3531
[48] Bioorganic and Medicinal Chemistry, 2013, vol. 21, # 11, p. 2843 - 2855
[49] Chemical Communications, 2013, vol. 49, # 46, p. 5313 - 5315
[50] Chemistry--A European Journal, 2015, vol. 21, # 1, p. 205 - 209
[51] Archiv der Pharmazie, 2013, vol. 346, # 7, p. 521 - 533
[52] Patent: EP2647622, 2013, A1, . Location in patent: Paragraph 0124
[53] Patent: US2013/317110, 2013, A1, . Location in patent: Paragraph 0139
[54] Bioorganic Chemistry, 2014, vol. 52, p. 1 - 7
[55] Bioorganic and Medicinal Chemistry Letters, 2014, vol. 24, # 1, p. 192 - 194
[56] Organic Letters, 2014, vol. 16, # 2, p. 390 - 393
[57] Molecules, 2013, vol. 18, # 12, p. 15737 - 15749
[58] Letters in Drug Design and Discovery, 2015, vol. 12, # 6, p. 488 - 494
[59] Chemistry - A European Journal, 2014, vol. 20, # 31, p. 9739 - 9743
[60] Patent: WO2014/125506, 2014, A2, . Location in patent: Page/Page column 21
[61] Journal of the Chemical Society of Pakistan, 2013, vol. 35, # 2, p. 449 - 455
[62] Journal of Fluorescence, 2014, vol. 24, # 4, p. 995 - 1001
[63] Turkish Journal of Chemistry, 2013, vol. 37, # 6, p. 909 - 916
[64] Journal of the American Chemical Society, 2014, vol. 136, # 33, p. 11590 - 11593
[65] Chemical Communications, 2014, vol. 50, # 77, p. 11303 - 11306
[66] Chemical Communications, 2015, vol. 51, # 1, p. 77 - 80
[67] Organic Letters, 2014, vol. 16, # 24, p. 6412 - 6415
[68] Organic Letters, 2015, vol. 17, # 5, p. 1228 - 1231
[69] European Journal of Medicinal Chemistry, 2015, vol. 90, p. 436 - 447
[70] Chemistry - A European Journal, 2015, vol. 21, # 26, p. 9364 - 9368
[71] European Journal of Medicinal Chemistry, 2014, vol. 90, p. 436 - 447
[72] Science China Chemistry, 2015, vol. 58, # 8, p. 1302 - 1309
[73] Synlett, 2015, vol. 26, # 11, p. 1455 - 1460
[74] Chinese Chemical Letters, 2016, vol. 27, # 1, p. 163 - 167
[75] Angewandte Chemie - International Edition, 2016, vol. 55, # 4, p. 1484 - 1488
[76] Journal of Molecular Structure, 2016, vol. 1117, p. 8 - 16
[77] Organic Letters, 2014, vol. 16, # 21, p. 5644 - 5647
[78] Journal of Organic Chemistry, 2016, vol. 81, # 8, p. 3416 - 3422
[79] Bioorganic and Medicinal Chemistry Letters, 2016, vol. 26, # 10, p. 2544 - 2546
[80] Bioorganic and Medicinal Chemistry Letters, 2016, vol. 26, # 14, p. 3263 - 3270
[81] Chemical Communications, 2016, vol. 52, # 70, p. 10676 - 10679
[82] Chinese Chemical Letters, 2016, vol. 27, # 9, p. 1547 - 1550
[83] Pharmacological Research, 2016, vol. 113, p. 610 - 625
[84] Chemical Biology and Drug Design, 2016, p. 664 - 676
[85] Tetrahedron Letters, 2016, vol. 57, # 48, p. 5372 - 5376
[86] Molecules, 2016, vol. 21, # 11,
[87] Organic Letters, 2016, vol. 18, # 21, p. 5536 - 5539
[88] Bioorganic and Medicinal Chemistry Letters, 2017, vol. 27, # 3, p. 393 - 397
[89] Tetrahedron, 2017, vol. 73, # 12, p. 1576 - 1582
[90] Journal of Organic Chemistry, 2017, vol. 82, # 6, p. 3245 - 3251
[91] Chemistry - A European Journal, 2017, vol. 23, # 15, p. 3577 - 3582
[92] Patent: WO2017/37672, 2017, A1, . Location in patent: Page/Page column 49; 50
[93] Journal of Molecular Structure, 2017, vol. 1138, p. 177 - 191
[94] Journal of Organic Chemistry, 2017, vol. 82, # 1, p. 420 - 430
[95] Chemical Communications, 2017, vol. 53, # 33, p. 4601 - 4604
[96] Organic Letters, 2017, vol. 19, # 10, p. 2746 - 2749
[97] Bioorganic and Medicinal Chemistry Letters, 2017, vol. 27, # 11, p. 2641 - 2644
[98] Synthesis (Germany), 2017, vol. 49, # 13, p. 2865 - 2872
[99] Journal of Medicinal Chemistry, 2017, vol. 60, # 15, p. 6622 - 6637
[100] Synthesis (Germany), 2017, vol. 49, # 17, p. 3937 - 3944
[101] Chemistry - A European Journal, 2018, vol. 24, # 10, p. 2360 - 2364
[102] Bioorganic and Medicinal Chemistry, 2018, vol. 26, # 8, p. 1740 - 1750
[103] Medicinal Chemistry Research, 2018, vol. 27, # 5, p. 1528 - 1537
[104] European Journal of Medicinal Chemistry, 2018, vol. 155, p. 197 - 209
[105] RSC Advances, 2018, vol. 8, # 50, p. 28668 - 28675
[106] Journal of Medicinal Chemistry, 2018, vol. 61, # 15, p. 6609 - 6628
[107] Chemical Communications, 2018, vol. 54, # 77, p. 10859 - 10862
[108] Patent: US4022900, 1977, A,
  • 3
  • [ 445-29-4 ]
  • [ 393-52-2 ]
Reference: [1] Patent: US4999356, 1991, A,
  • 4
  • [ 445-29-4 ]
  • [ 393-52-2 ]
Reference: [1] Patent: US4999356, 1991, A,
  • 5
  • [ 445-29-4 ]
  • [ 393-52-2 ]
Reference: [1] Patent: US4195023, 1980, A,
  • 6
  • [ 10026-13-8 ]
  • [ 108-95-2 ]
  • [ 445-29-4 ]
  • [ 393-52-2 ]
Reference: [1] Patent: US4999356, 1991, A,
  • 7
  • [ 10026-13-8 ]
  • [ 108-95-2 ]
  • [ 445-29-4 ]
  • [ 393-52-2 ]
Reference: [1] Patent: US4999356, 1991, A,
  • 8
  • [ 3416-93-1 ]
  • [ 445-29-4 ]
  • [ 393-52-2 ]
Reference: [1] Journal of the American Chemical Society, 2014, vol. 136, # 9, p. 3354 - 3357
  • 9
  • [ 79-37-8 ]
  • [ 445-29-4 ]
  • [ 393-52-2 ]
Reference: [1] Chemistry - A European Journal, 2017, vol. 23, # 50, p. 12149 - 12152
  • 10
  • [ 445-29-4 ]
  • [ 7364-27-4 ]
Reference: [1] Patent: WO2017/46318, 2017, A1,
  • 11
  • [ 95-52-3 ]
  • [ 7726-95-6 ]
  • [ 446-48-0 ]
  • [ 446-51-5 ]
  • [ 446-52-6 ]
  • [ 445-29-4 ]
Reference: [1] Journal of the Chemical Society, 1926, p. 220
  • 12
  • [ 110-91-8 ]
  • [ 445-29-4 ]
  • [ 42106-48-9 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2008, vol. 18, # 18, p. 5134 - 5139
  • 13
  • [ 445-29-4 ]
  • [ 7304-32-7 ]
YieldReaction ConditionsOperation in experiment
93% at 10 - 25℃; for 2 h; A35-a intermediate 36: 2-Fluoro- -nitrobenzoic acidNitric acid (60percent solution, 5.0 mL) was carefully added to a cooled solution of concentrate sulfuric acid (5.0 mL) so that the temperature did not exceed 10 °C. 2-f uorobenzoic acid (2.1 g, 15.0 mmol) was added by small portions while maintaining temperature between 15 and 25 °C. The mixture was stirred for 2 h at room temperature. Ice was added and the precipitate was filtered. After drying at room temperature, intermediate 36 was obtained as a white powder. Yield: 93percent; mp 135-137 °C; 1H NMR (300 MHz, OMSO-d6): δ = 7.32 (t, 1 H, H3, 3 J H3_H4 = J H3-F = 9.2 Hz), 8.43 (dt, 1 H, H JH4.H3 = 9.2 Hz, JH4.F = JH4.H6 = 3.5 Hz), 8.89 (dd, 1H, 3/4, 4JH6.F = 5.8 Hz, 4JH6.H4 = 3.0 Hz); 13C NMR (75 MHz, DMSO- d6): δ = 118.7 (d, Ci, 2JC-F = 10.9 Hz), 118.7 (d, C3, 2JC-F = 25.0 Hz), 128.9 (d, C6> 3JC-F = 2.2 Hz), 130.6 (d, C4, 3JC- = 10.9 Hz), 143.9 (C5), 165.7 (d, C2, 1JC.F = 272.0 Hz), 166.7 (d, COOH, 3Jc- = 3.8 Hz).
Reference: [1] Patent: WO2012/85003, 2012, A1, . Location in patent: Page/Page column 83
[2] Journal of Organic Chemistry, 2008, vol. 73, # 2, p. 538 - 549
[3] Journal of Heterocyclic Chemistry, 1998, vol. 35, # 6, p. 1301 - 1304
[4] Journal of Medicinal Chemistry, 2003, vol. 46, # 10, p. 1905 - 1917
[5] Australian Journal of Chemistry, 1981, vol. 34, # 5, p. 969 - 979
[6] Patent: US4565872, 1986, A,
[7] Patent: US4380543, 1983, A,
[8] Patent: US4400386, 1983, A,
  • 14
  • [ 445-29-4 ]
  • [ 7304-32-7 ]
  • [ 317-46-4 ]
Reference: [1] Bulletin des Societes Chimiques Belges, 1930, vol. 39, p. 101
[2] Recueil des Travaux Chimiques des Pays-Bas, 1914, vol. 33, p. 336
  • 15
  • [ 445-29-4 ]
  • [ 2965-22-2 ]
Reference: [1] Patent: WO2012/85003, 2012, A1,
  • 16
  • [ 67-56-1 ]
  • [ 445-29-4 ]
  • [ 2965-22-2 ]
Reference: [1] Journal of Organic Chemistry, 1990, vol. 55, # 7, p. 2034 - 2044
  • 17
  • [ 445-29-4 ]
  • [ 348-52-7 ]
YieldReaction ConditionsOperation in experiment
64% With N-iodo-succinimide; [4,4’-bis(tert-butyl)-2,2’-bipyridine]bis[3,5-difluoro-2-[5-(trifluoromethyl)-2-pyridinyl]phenyl]iridium(III) hexafluorophosphate; iodine; caesium carbonate In 1,2-dichloro-ethane at 50℃; for 24 h; Inert atmosphere; Irradiation; Sealed tube General procedure: To a 15 mL test tube with septum Cs2CO3 (0.6 mmol, 195 mg), aromaticcarboxylic acid (1) (0.3 mmol), [Ir(dF(CF3)ppy)2dtbbpy]PF6 (D) (6 μmmol, 6.7 mg), Niodosuccinimide(NIS) (0.9 mmol, 202.5 mg) and I2 (15 μmol, 5 molpercent) were added. The tube was evacuated and backfilled with argon for three times, and then 3 mL of dry 1,2-dichloroethane(DCE) was added through a syringer under argon. The tube was sealed with Parafilm M® andplaced in an oil bath with a contact thermometer, and the reaction was carried out at 50 °C underirradiation with 6 × 5 W blue LEDs (λmax = 455 nm). After 24 or 36 h, the resulting mixture wasfiltered through a 2 cm thick pad of silica, and the silica was washed with dichloromethane (DCM)(50 mL). The filtrate was collected and the solvent was removed in vacuo. The crude residue waspurified by silica gel flash column chromatography to provide the target product (2). (Note: Thereaction was very sensitive to moisture, and the yields sharply decreased to less than 5percent when0.01 equivalent of H2O was added to the reaction system).
Reference: [1] Synlett, 2018, vol. 29, # 12, p. 1572 - 1577
  • 18
  • [ 445-29-4 ]
  • [ 446-24-2 ]
Reference: [1] European Journal of Medicinal Chemistry, 2017, vol. 138, p. 396 - 406
[2] Heterocyclic Communications, 2002, vol. 8, # 6, p. 601 - 606
[3] Journal of Heterocyclic Chemistry, 1989, vol. 26, p. 257 - 264
[4] Monatshefte fur Chemie, 2010, vol. 141, # 4, p. 479 - 484
[5] Journal of Agricultural and Food Chemistry, 2011, vol. 59, # 18, p. 9892 - 9900
[6] Bioorganic and Medicinal Chemistry, 2012, vol. 20, # 11, p. 3615 - 3621
[7] Medicinal Chemistry, 2012, vol. 8, # 6, p. 1190 - 1197,8
[8] Medicinal Chemistry, 2012, vol. 8, # 6, p. 1190 - 1197
[9] Bioorganic and Medicinal Chemistry, 2013, vol. 21, # 8, p. 2286 - 2297
[10] Journal of Heterocyclic Chemistry, 2013, vol. 50, # 4, p. 945 - 948
[11] Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2013, vol. 115, p. 683 - 689
[12] Chemical Biology and Drug Design, 2013, vol. 82, # 5, p. 546 - 556
[13] Bioorganic and Medicinal Chemistry Letters, 2014, vol. 24, # 1, p. 192 - 194
[14] Tetrahedron, 2014, vol. 70, # 12, p. 2190 - 2194
[15] Journal of Fluorescence, 2014, vol. 24, # 4, p. 995 - 1001
[16] Journal of Heterocyclic Chemistry, 2015, vol. 52, # 5, p. 1296 - 1301
[17] Bioorganic and Medicinal Chemistry, 2015, vol. 23, # 17, p. 6014 - 6024
[18] Transition Metal Chemistry, 2015, vol. 40, # 6, p. 665 - 671
[19] Chinese Chemical Letters, 2016, vol. 27, # 1, p. 163 - 167
[20] Zeitschrift fur Naturforschung - Section B Journal of Chemical Sciences, 2015, vol. 70, # 8, p. 609 - 616
[21] Journal of Molecular Structure, 2016, vol. 1117, p. 8 - 16
[22] Medicinal Chemistry Research, 2016, vol. 25, # 4, p. 627 - 643
[23] European Journal of Medicinal Chemistry, 2016, vol. 120, p. 134 - 147
[24] Journal of the Brazilian Chemical Society, 2016, vol. 27, # 11, p. 1998 - 2010
[25] Journal of the Chemical Society of Pakistan, 2016, vol. 38, # 5, p. 864 - 881
[26] Journal of Molecular Structure, 2017, vol. 1138, p. 177 - 191
[27] Chemical Biology and Drug Design, 2017, vol. 90, # 2, p. 236 - 243
[28] RSC Advances, 2018, vol. 8, # 12, p. 6306 - 6314
[29] Journal of Chemistry, 2017, vol. 2017,
[30] Bioorganic and Medicinal Chemistry, 2018, vol. 26, # 8, p. 1971 - 1985
[31] European Journal of Medicinal Chemistry, 2018, vol. 159, p. 126 - 142
  • 19
  • [ 64-17-5 ]
  • [ 445-29-4 ]
  • [ 443-26-5 ]
Reference: [1] Journal of the American Chemical Society, 2017, vol. 139, # 23, p. 7745 - 7748
[2] Bioorganic and Medicinal Chemistry, 2010, vol. 18, # 22, p. 7836 - 7841
[3] Journal of Agricultural and Food Chemistry, 2011, vol. 59, # 18, p. 9892 - 9900
[4] Bioorganic and Medicinal Chemistry, 2013, vol. 21, # 8, p. 2286 - 2297
[5] Journal of Heterocyclic Chemistry, 2013, vol. 50, # 4, p. 945 - 948
[6] Transition Metal Chemistry, 2015, vol. 40, # 6, p. 665 - 671
[7] Tetrahedron, 2014, vol. 70, # 12, p. 2190 - 2194
[8] Journal of Heterocyclic Chemistry, 2015, vol. 52, # 5, p. 1296 - 1301
[9] Bioorganic and Medicinal Chemistry, 2015, vol. 23, # 17, p. 6014 - 6024
[10] Chinese Chemical Letters, 2016, vol. 27, # 1, p. 163 - 167
[11] European Journal of Medicinal Chemistry, 2016, vol. 120, p. 134 - 147
[12] Journal of the Brazilian Chemical Society, 2016, vol. 27, # 11, p. 1998 - 2010
[13] Chemical Biology and Drug Design, 2017, vol. 90, # 2, p. 236 - 243
[14] RSC Advances, 2018, vol. 8, # 12, p. 6306 - 6314
  • 20
  • [ 591-87-7 ]
  • [ 443-26-5 ]
  • [ 445-29-4 ]
Reference: [1] Angewandte Chemie - International Edition, 2018, vol. 57, # 44, p. 14580 - 14584[2] Angew. Chem., 2018, vol. 130, p. 14788 - 14792,5
  • 21
  • [ 446-52-6 ]
  • [ 445-28-3 ]
  • [ 445-29-4 ]
YieldReaction ConditionsOperation in experiment
24%
Stage #1: at -33℃; for 1 h; Inert atmosphere
Stage #2: at -33℃; for 1 h; Inert atmosphere; Reflux
General procedure: Under an argon atmosphere, liquid NH3 (25 mL) was condensedin a two-neck round-bottom flask immersed in a dry ice coolingbath and equipped with a dry ice reflux condenser. Aldehyde(7.34 mmol) was added, and the resulting solution (or suspension)was stirred for 1 h. KMnO4 (7.34 mmol, 1.16 g) was added,the cooling bath was removed, and the reaction mixture wasstirred for another hour with gentle reflux of NH3. Na2SO3 (22.0mmol, 2.78 g) was added, the reflux condenser was removed,and the NH3 was allowed to evaporate spontaneously. The darkbrownresidue was treated with 6 M HCl (30 mL), and theresulting precipitate was filtered, washed with H2O (100 mL)and sat. aq NaHCO3 (20 mL). All products were recrystallizedfrom EtOH.
24%
Stage #1: at -33℃; for 1 h; Inert atmosphere
Stage #2: for 1 h; Inert atmosphere; Reflux
General procedure: Under an argon atmosphere, liquid NH3 (25 mL) was condensedin a two-neck round-bottom flask immersed in a dry ice coolingbath and equipped with a dry ice reflux condenser. Aldehyde (7.34 mmol) was added, and the resulting solution (or suspension)was stirred for 1 h. KMnO4 (7.34 mmol, 1.16 g) was added,the cooling bath was removed, and the reaction mixture wasstirred for another hour with gentle reflux of NH3. Na2SO3 (22.0mmol, 2.78 g) was added, the reflux condenser was removed,and the NH3 was allowed to evaporate spontaneously. The darkbrownresidue was treated with 6 M HCl (30 mL), and theresulting precipitate was filtered, washed with H2O (100 mL)and sat. aq NaHCO3 (20 mL). All products were recrystallizedfrom EtOH.
Reference: [1] Synlett, 2014, vol. 25, # 9,
[2] Synlett, 2015, vol. 26, # 1, p. 84 - 86
  • 22
  • [ 75-64-9 ]
  • [ 445-29-4 ]
  • [ 445-28-3 ]
  • [ 61752-07-6 ]
Reference: [1] Organic Letters, 2010, vol. 12, # 10, p. 2406 - 2409
  • 23
  • [ 445-29-4 ]
  • [ 445-28-3 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2016, vol. 26, # 10, p. 2544 - 2546
[2] Bioorganic and Medicinal Chemistry Letters, 2016, vol. 26, # 14, p. 3263 - 3270
[3] Patent: CN105541753, 2016, A, . Location in patent: Paragraph 0007;
  • 24
  • [ 57-13-6 ]
  • [ 445-29-4 ]
  • [ 445-28-3 ]
Reference: [1] Pharmaceutical Chemistry Journal, 1994, vol. 28, # 5, p. 335 - 338[2] Khimiko-Farmatsevticheskii Zhurnal, 1994, vol. 28, # 5, p. 35 - 37
  • 25
  • [ 445-29-4 ]
  • [ 1479-24-9 ]
Reference: [1] Bioorganic and Medicinal Chemistry, 2013, vol. 21, # 11, p. 2843 - 2855
[2] Archiv der Pharmazie, 2013, vol. 346, # 7, p. 521 - 533
[3] Patent: EP2799437, 2014, A1,
[4] Patent: US2014/364431, 2014, A1,
[5] Patent: WO2017/37672, 2017, A1,
[6] Patent: WO2017/37672, 2017, A1,
  • 26
  • [ 6148-64-7 ]
  • [ 445-29-4 ]
  • [ 1479-24-9 ]
Reference: [1] RSC Advances, 2018, vol. 8, # 27, p. 15009 - 15020
  • 27
  • [ 445-29-4 ]
  • [ 56741-33-4 ]
Reference: [1] Journal of Heterocyclic Chemistry, 1998, vol. 35, # 6, p. 1301 - 1304
  • 28
  • [ 445-29-4 ]
  • [ 7304-32-7 ]
  • [ 317-46-4 ]
Reference: [1] Bulletin des Societes Chimiques Belges, 1930, vol. 39, p. 101
[2] Recueil des Travaux Chimiques des Pays-Bas, 1914, vol. 33, p. 336
  • 29
  • [ 445-29-4 ]
  • [ 111771-08-5 ]
Reference: [1] Angewandte Chemie - International Edition, 2008, vol. 47, # 28, p. 5215 - 5219
[2] ACS Catalysis, 2018, vol. 8, # 2, p. 920 - 925
  • 30
  • [ 445-29-4 ]
  • [ 146328-85-0 ]
YieldReaction ConditionsOperation in experiment
87.9% With sodium periodate; sulfuric acid; sodium bromide In water; acetic acid at 30 - 65℃; First, sodium periodate solution was configured: 7.7 g (36 mmol) of sodium periodate was dissolved in 40 ml of water and 26 ml of acetic acid.Next, add 10 g (71.4 mmol) of 2-fluorobenzoic acid, 7.35 g (71.4 mmol) of sodium bromide and sodium periodate solution to the reaction flask and heat to 30°C.At this temperature, 6.0 ml concentrated sulfuric acid was slowly added dropwise. After adding concentrated sulfuric acid, heat up to 50-65°C and react at this temperature for 2-3 hours.. Thin layer chromatography (TLC) detection reaction is completed, cooled, poured into ice water, solid precipitated, filtered,The filter cake was washed with water several times to obtain the product 2-chloro-5-bromobenzoic acid 14.6 g, yield 87.9percent.
77% With potassium bromate; sulfuric acid In water at 90℃; for 2 h; 2-Fiuorobenzoic acid (1.0 g, 7.14 mmol), KBr03 (2.38 g, 14.28 mmol) and water (2 ml)were added to H2S04 (5 ml). This reaction mixture was stirred for 2 h at 90 °C. Theresulting mixture was extracted with ethyl acetate. The organic layer was dried over Na2S04, filtered and concentrated in vacuo to afford the crude product (1.2 g, 77 percent) as awhite solid.
Reference: [1] Journal of Organometallic Chemistry, 2008, vol. 693, # 18, p. 3081 - 3091
[2] Patent: CN107954852, 2018, A, . Location in patent: Paragraph 0035-0037
[3] Patent: WO2017/46318, 2017, A1, . Location in patent: Page/Page column 54
  • 31
  • [ 445-29-4 ]
  • [ 124700-41-0 ]
Reference: [1] Journal of Medicinal Chemistry, 2006, vol. 49, # 5, p. 1506 - 1508
  • 32
  • [ 445-29-4 ]
  • [ 37098-75-2 ]
YieldReaction ConditionsOperation in experiment
78.1% With chlorosulfonic acid In water (1a)
5-Chlorosulphonyl-2-fluorobenzoic acid (Compound VIA X=F)
Commercially available 2-fluorobenzoic acid (75 g, 0.54 Mol) was added to chlorosulphonic acid (320 g) over 15 minutes, stirred for 30 minutes then heated to 90° C. for 41/2 hrs.
Once cool, the reaction was quenched onto ice/water (1.5 kg/324 ml) and granulated for 1 hr.
The precipitated product was filtered, water washed and dried at 50° C. under vacuo to give the title compound (99.7 g, 78.1percent) as a white solid.
73% With chlorosulfonic acid In dichloromethane at 40℃; for 48 h; 2. Synthesis of Starting Material 21 or 21-1; The intensive trouble-shooting of the 4-step sequence from 2-fluorobenzoic acid (17) to 21 succeeded in an overall yield improvement from 17 to 50percent. The main enhancement was achieved by optimizing the reaction conditions to 19 with sodium sulfite followed by the alkylation reaction with R1hal (hal=I, Cl, Br) yielding 21 after saponification and crystallization. In a non-optimized reaction a one-pot procedure from 20 to 21-1 was demonstrated applying sodium sulfite in NaOH 32percent followed by the treatment of ClCH2CO2H yielding 21-1 in 61percent analogue to WO02/07238.
73% at 0 - 75℃; To a 500mL three-mouthed flask was added 50mL of chlorosulfonic acid and a stirred, and cooled to 0 deg. C, was added portionwise 18g 2-fluorobenzoic acid was slowly warmed to 75 deg. C, heated overnight, after which the reaction cooled to room temperature, with the stirring was poured into 400mL ice water, a large number of yellow solid was filtered, the cake washed with 30mL toluene and water 3 times. And dried in vacuo to give a yellow solid 22.6g. It was used directly in the next step, yield: 73percent.
72.2% at 0 - 75℃; for 5 h; 416g of chlorosulfonic acid was added to a 1000ml reaction flask and cooled to below 0°C with iced saline.Stir and add 100g (0.71mol) of o-fluorobenzoic acid in portions; heat with oil bath, heat to 75°C, stir for 5 hours; cool to room temperature, drop the reaction into 300g ice, produce a white solid, filter, wash, Drying gave 123 g of a white solid, yield 72.2percent.
40.4% at 0 - 75℃; To chlorosulfonic acid (23.8 mL, 350 mmol) cooled to 0 °C was added portionwise 2-fluorobenzoic acid (5 g, 35 mmol). After complete addition, the yellow solution was allowed to warm to room temperature, then heated to 75 °C overnight. The reaction mixture was cooled to room temperature and then added dropwise to ice- water (150 mL). The white precipitate was filtered, washed with water, and dried in vacuo to afford the desired product B02 as a white solid (3.37 g, 40.4 percent).
10.5 g at 0℃; for 1 h; 5-(N-((1-Cyclopropyl-1H-1,2,3-triazol-4-yl)methyl)sulfamoyl)-N-(3,4- difluorophenyl)-2-fluorobenzamide (13) 2-fluorobenzoic acid 9 (10.0 g, 71.4 mmol) was added to chlorosulfonic acid (50 mL) at 0 °C and the mixture was stirred at 0 °C for 1 h. The reaction mixture was then slowly poured onto ice. The precipitate formed was filtered, rinsed off with water (3 x 100 mL) and dried under vacuum overnight to yield 5-(chlorosulfonyl)-2- fluorobenzoic acid 10 as a brownish solid (10.5 g, 44.0 mmol). 5-(chlorosulfonyl)-2- fluorobenzoic acid 10 (10.0 g, 41.9 mmol) was added to 60 mL of SOCl2 at room temperature and the mixture was refluxed for 1.5 h. After removal of SOCl2 in vacuo, the residual oil was solubilized in toluene (150 mL) and 3,4-difluoroaniline (6.5 g, 50.3 mmol) was added. The mixture was stirred at 100 °C for 4 h and then cooled down to room temperature. The solution was then poured into a saturated solution of ammonium chloride (200 mL) and extracted with EtOAc (3 x 200 mL). The combined organic layers were dried over sodium sulfate and concentrated in vacuo. The resulting residue was purified by flash chromatography (Hexanes/EtOAc = 6:4 v/v) to yield 3- ((3,4-difluorophenyl)carbamoyl)-4-fluorobenzene-1-sulfonyl chloride 11 (92percent, 13.51 g, 38.6 mmol). To a solution of 3-((3,4-difluorophenyl)carbamoyl)-4-fluorobenzene-1- sulfonyl chloride 11 (10.0 g, 28.6 mmol) in CH2Cl2 (200 mL) at 0 °C were added propargylamine hydrochloride (3.1 g, 34.3 mmol) and Et3N (7.8 mL, 57.2 mmol). The reaction mixture was stirred overnight at room temperature and then poured into a saturated solution of ammonium chloride (250 mL). After extraction with CH2Cl2 (3 x 100 mL), the combined organic layers were dried over sodium sulfate and finally concentrated in vacuo. The resulting solid was washed with diethyl ether (50 mL) and hexanes (50 mL) to yield N-(3,4-difluorophenyl)-2-fluoro-5-(N-(prop-2-yn-1- yl)sulfamoyl)benzamide 12 (74percent, 7.8 g, 21.1 mmol) as a white powder. A solution of bromocyclopropane (0.6 mL, 4.9 mmol) and sodium azide (483 mg, 7.4 mmol) in water (1 mL) was heated under microwave irradiation for 30 minutes at 120 °C. To this solution were added a solution of compound 12 (0.1 g, 0.3 mmol) in acetonitrile (1 mL), sodium ascorbate (10 mg, 0.05 mmol) and copper sulfate (20 mg, 0.12 mmol). (0096) The reaction mixture was then heated for 30 minutes at 80 °C under microwave irradiation before being poured into a saturated solution of ammonium chloride (50 mL). After extraction with EtOAc (3 x 50 mL), the combined organic layers were dried over sodium sulfate and concentrated in vacuo. The resulting residue was purified by flash chromatography (Hexanes:EtOAc = 6:4 v/v) giving compound 13 as a white powder (19percent, 23 mg, 0.05 mmol). 1H NMR (400 MHz, Acetone-d6) δ 9.92 (s, 1H), 8.25 (dd, J = 6.6, 2.5 Hz, 1H), 8.06– 7.95 (m, 2H), 7.77 (s, 1H), 7.58– 7.52 (m, 1H), 7.48 (dd, J = 10.1, 8.7 Hz, 1H), 7.37 (dt, J = 10.6, 9.0 Hz, 1H), 7.21 (brs, 1H), 6.11– 5.94 (m, 1H), 5.32– 5.16 (m, 1H), 4.99 (dt, J = 6.0, 1.5 Hz, 2H), 4.32 (s, 2H). 13C NMR (101 MHz, Acetone-d6) δ 188.9, 167.9, 162.1, 150.2, 149.2 (d, J = 12.9 Hz), 146.8 (d, J = 13.0 Hz), 142.8, 137.9 (d, J = 5.9 Hz), 128.5, 124.6, 120.4– 118.2 (m), 117.5 (dd, J = 6.0, 3.6 Hz), 110.6 (d, J = 22.1 Hz), 81.5, 73.3, 33.2, 29.7, 12.8 (d, J = 9.6 Hz). 19F NMR (377 MHz, Acetone-d6) δ -110.6 (s), -139.6– - 139.7 (m), -146.1– -146.3 (m). HRMS (ESI): m/z [M+H]+ calcd for C19H17F3N5O3S: 452.1004, found: 452.0999.

Reference: [1] Patent: US6207829, 2001, B1,
[2] European Journal of Medicinal Chemistry, 2017, vol. 138, p. 407 - 421
[3] Journal of Medicinal Chemistry, 2010, vol. 53, # 12, p. 4603 - 4614
[4] Patent: US2008/221327, 2008, A1, . Location in patent: Page/Page column 4-5
[5] Patent: CN105712952, 2016, A, . Location in patent: Paragraph 0346; 0347; 0348
[6] Patent: CN104628679, 2018, B, . Location in patent: Paragraph 0066-0068
[7] Patent: WO2013/96744, 2013, A1, . Location in patent: Page/Page column 224
[8] Patent: US3992441, 1976, A,
[9] Patent: US3992441, 1976, A,
[10] Patent: WO2008/70707, 2008, A1, . Location in patent: Page/Page column 22-23
[11] Angewandte Chemie - International Edition, 2017, vol. 56, # 1, p. 248 - 253[12] Angew. Chem., 2017, vol. 129, # 1, p. 254 - 259,6
[13] Patent: WO2017/156255, 2017, A1, . Location in patent: Page/Page column 84; 85
  • 33
  • [ 445-29-4 ]
  • [ 651735-59-0 ]
Reference: [1] Journal of Organic Chemistry, 2003, vol. 68, # 26, p. 10195 - 10198
[2] Patent: EP2647622, 2013, A1,
[3] Patent: US2013/317110, 2013, A1,
  • 34
  • [ 445-29-4 ]
  • [ 57381-59-6 ]
Reference: [1] Patent: WO2017/46318, 2017, A1,
  • 35
  • [ 199447-10-4 ]
  • [ 445-29-4 ]
  • [ 775304-57-9 ]
YieldReaction ConditionsOperation in experiment
65% With tetrachloromethane; diethoxymethylsilane; Bis(p-nitrophenyl) phosphate; triphenylphosphine In toluene at 120℃; for 24 h; Reflux; Large scale To the reactor was added o-fluorobenzoic acid (4,140 g, 1 mol), compound 3 (180 g, 1 mol), triphenylphosphine(52.4 g, 0.2 mol) carbon tetrachloride (152 g, 1 mol), diethoxymethylsilane (202.6 g, 1.2 mol)Bis (p-nitrophenyl) phosphate (17.1 g, 0.05 mol),500mL of toluene. 120 oil bath heated to reflux condensation reaction for 24 hours. Until the reaction liquid coldAfter that, it was extracted with ethyl acetate, dried over anhydrous sodium sulfate and concentrated to dryness under reduced pressure. The residue was purified by column chromatography to give the title compoundAtaluren (1,184.6 g) as a white solid in 65percent yield
Reference: [1] Patent: CN106279057, 2017, A, . Location in patent: Paragraph 0023; 0024
  • 36
  • [ 445-29-4 ]
  • [ 775304-57-9 ]
Reference: [1] New Journal of Chemistry, 2014, vol. 38, # 7, p. 3062 - 3070
  • 37
  • [ 6638-79-5 ]
  • [ 445-29-4 ]
  • [ 198967-24-7 ]
YieldReaction ConditionsOperation in experiment
73% With N-ethyl-N,N-diisopropylamine; HATU In dichloromethane at 20℃; for 2 h; 2-Fluoro-N-methoxy-N-methylbenzamide was prepared in 73percent yield according to the Example 1 , Step A substituting 6-bromopicolinic acid for 2-fluorobenzoic acid.
Reference: [1] Patent: WO2015/140133, 2015, A1, . Location in patent: Page/Page column 96
  • 38
  • [ 75-24-1 ]
  • [ 445-29-4 ]
  • [ 90259-27-1 ]
Reference: [1] Journal of the American Chemical Society, 2016, vol. 138, # 32, p. 10132 - 10135
  • 39
  • [ 881676-32-0 ]
  • [ 445-29-4 ]
  • [ 881674-56-2 ]
YieldReaction ConditionsOperation in experiment
96.5% With bis-triphenylphosphine-palladium(II) chloride; 1,10-Phenanthroline; copper (I) acetate; sodium hydroxide In dimethyl sulfoxide at 140℃; for 5 h; Inert atmosphere Dimethyl sulfoxide (200 mL) was added to a 500 mL three-neck flask, and 2-fluorobenzoic acid (II) (14.2 g, 0.1 mol) was added under nitrogen.5-bromopyrrole-3-carbaldehyde (III) (35.5 g, 0.2 mol), sodium hydroxide (40.1 g, 1 mol), Pd(PPh3)2Cl2 (14.1 g, 0.02 mol), CuOAc (4.9 g, 0.04 mol) ,1,10-Phenanthroline (7.3g, 0.04mol), stirring, heating to 140°C, reaction for 5h,The reaction was completed by HPLC (2-fluorobenzoic acid (II) content is less than 1percent), the temperature was lowered to 20°C, the pH was adjusted to 6 with 5percent aqueous hydrochloric acid solution, and the solid was slowly precipitated by adding water.The solid was extracted with ethyl acetate (50 mL X 3).The resulting organic phase was washed with saturated sodium bicarbonate solution (100 mL) and saturated sodium chloride solution (100 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to 80 g and re-crystallized by the dropwise addition of petroleum ether (150 mL).Filtration drying gave a reddish solid product (18.5 g, yield: 96.5percent based on 2-fluorobenzoic acid (II)).
Reference: [1] Patent: CN107935902, 2018, A, . Location in patent: Paragraph 0044-0055
  • 40
  • [ 445-29-4 ]
  • [ 845614-11-1 ]
Reference: [1] Patent: CN104628679, 2018, B,
Same Skeleton Products
Historical Records

Pharmaceutical Intermediates of
[ 445-29-4 ]

Bitopertin Related Intermediates

Chemical Structure| 89402-42-6

[ 89402-42-6 ]

2,3-Difluoro-5-(trifluoromethyl)pyridine

Related Functional Groups of
[ 445-29-4 ]

Fluorinated Building Blocks

Chemical Structure| 1583-58-0

[ 1583-58-0 ]

2,4-Difluorobenzoic acid

Similarity: 0.98

Chemical Structure| 261763-37-5

[ 261763-37-5 ]

2,3-Difluoro-4-methylbenzoic acid

Similarity: 0.96

Chemical Structure| 350-28-7

[ 350-28-7 ]

3-Fluoro-4-methylbenzoic acid

Similarity: 0.96

Chemical Structure| 455-38-9

[ 455-38-9 ]

3-Fluorobenzoic acid

Similarity: 0.93

Chemical Structure| 456-22-4

[ 456-22-4 ]

4-Fluorobenzoic acid

Similarity: 0.93

Aryls

Chemical Structure| 1583-58-0

[ 1583-58-0 ]

2,4-Difluorobenzoic acid

Similarity: 0.98

Chemical Structure| 261763-37-5

[ 261763-37-5 ]

2,3-Difluoro-4-methylbenzoic acid

Similarity: 0.96

Chemical Structure| 350-28-7

[ 350-28-7 ]

3-Fluoro-4-methylbenzoic acid

Similarity: 0.96

Chemical Structure| 455-38-9

[ 455-38-9 ]

3-Fluorobenzoic acid

Similarity: 0.93

Chemical Structure| 456-22-4

[ 456-22-4 ]

4-Fluorobenzoic acid

Similarity: 0.93

Carboxylic Acids

Chemical Structure| 1583-58-0

[ 1583-58-0 ]

2,4-Difluorobenzoic acid

Similarity: 0.98

Chemical Structure| 261763-37-5

[ 261763-37-5 ]

2,3-Difluoro-4-methylbenzoic acid

Similarity: 0.96

Chemical Structure| 350-28-7

[ 350-28-7 ]

3-Fluoro-4-methylbenzoic acid

Similarity: 0.96

Chemical Structure| 455-38-9

[ 455-38-9 ]

3-Fluorobenzoic acid

Similarity: 0.93

Chemical Structure| 456-22-4

[ 456-22-4 ]

4-Fluorobenzoic acid

Similarity: 0.93